首页> 外文期刊>Bioorganic and medicinal chemistry >Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery
【24h】

Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery

机译:合理设计基于尿素的谷氨酸羧肽酶II(GCPII)抑制剂,作为针对特定药物靶向和递送的多功能工具

获取原文
获取原文并翻译 | 示例
           

摘要

Glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), is an established prostate cancer marker and is considered a promising target for specific anticancer drug delivery. Low-molecular-weight inhibitors of GCPII are advantageous specific ligands for this purpose. However, they must be modified with a linker to enable connection of the ligand with an imaging molecule, anticancer drug, and/or nanocarrier. Here, we describe a structure-activity relationship (SAR) study of GCPII inhibitors with linkers suitable for imaging and drug delivery. Structure-assisted inhibitor design and targeting of a specific GCPII exosite resulted in a 7-fold improvement in Ki value compared to the parent structure. X-ray structural analysis of the inhibitor series led to the identification of several inhibitor binding modes. We also optimized the length of the inhibitor linker for effective attachment to a biotin-binding molecule and showed that the optimized inhibitor could be used to target nanoparticles to cells expressing GCPII.
机译:谷氨酸羧肽酶II(GCPII),也称为前列腺特异膜抗原(PSMA),是已建立的前列腺癌标志物,被认为是特定抗癌药物递送的有希望的靶标。为此目的,GCPII的低分子量抑制剂是有利的特异性配体。然而,必须用接头修饰它们以使配体与成像分子,抗癌药和/或纳米载体连接。在这里,我们描述了GCPII抑制剂与适用于成像和药物递送的接头的构效关系(SAR)研究。与母体结构相比,结构辅助抑制剂的设计和靶向特定GCPII外位的Ki值提高了7倍。抑制剂系列的X射线结构分析导致鉴定了几种抑制剂结合模式。我们还优化了有效连接生物素结合分子的抑制剂接头的长度,并表明优化的抑制剂可用于将纳米粒子靶向表达GCPII的细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号